What is he best known for?
The fields of study he is best known for:
- Organic chemistry
- Enzyme
- Catalysis
His scientific interests lie mostly in Combinatorial chemistry, Acetylcholinesterase, Linker, Nerve agent and Stereochemistry.
His Combinatorial chemistry research is multidisciplinary, relying on both BODIPY, Catalysis, Monoclonal antibody, Peptide and Solubility.
Acetylcholinesterase is the subject of his research, which falls under Enzyme.
Protease, Organic chemistry and Biochemistry are fields of study that intersect with his Linker study.
His research in Nerve agent intersects with topics in Hydrolysis, Aché, Pharmacology and Reactivity.
Pierre-Yves Renard studies Moiety which is a part of Stereochemistry.
His most cited work include:
- Reactivators of Acetylcholinesterase Inhibited by Organophosphorus Nerve Agents (208 citations)
- Crystal structures of human cholinesterases in complex with huprine W and tacrine: elements of specificity for anti-Alzheimer's drugs targeting acetyl- and butyryl-cholinesterase. (185 citations)
- Water-Soluble BODIPY Derivatives (139 citations)
What are the main themes of his work throughout his whole career to date?
His main research concerns Organic chemistry, Combinatorial chemistry, Acetylcholinesterase, Stereochemistry and Moiety.
Pierre-Yves Renard merges Organic chemistry with Linker in his research.
His study in Combinatorial chemistry is interdisciplinary in nature, drawing from both Reactivity, Molecule, Nucleophile and Peptide.
His Acetylcholinesterase study is focused on Enzyme in general.
Pierre-Yves Renard works mostly in the field of Stereochemistry, limiting it down to concerns involving Monoclonal antibody and, occasionally, Immunoassay.
His research integrates issues of Ketone, Quinoline and Biochip in his study of Moiety.
He most often published in these fields:
- Organic chemistry (60.00%)
- Combinatorial chemistry (47.14%)
- Acetylcholinesterase (28.93%)
What were the highlights of his more recent work (between 2016-2021)?
- Acetylcholinesterase (28.93%)
- Pharmacology (10.36%)
- Nerve agent (22.50%)
In recent papers he was focusing on the following fields of study:
Pierre-Yves Renard mainly investigates Acetylcholinesterase, Pharmacology, Nerve agent, Combinatorial chemistry and Stereochemistry.
His studies in Acetylcholinesterase integrate themes in fields like Nicotinic Receptors and Active site.
His Nerve agent research focuses on subjects like Oxime, which are linked to Paraoxon.
Pierre-Yves Renard studies Combinatorial chemistry, focusing on Bioconjugation in particular.
His Stereochemistry research incorporates themes from Pyridinium, Structure–activity relationship and Phosphorylation.
In his study, which falls under the umbrella issue of Covalent bond, Moiety is strongly linked to Substituent.
Between 2016 and 2021, his most popular works were:
- Azo-Based Fluorogenic Probes for Biosensing and Bioimaging: Recent Advances and Upcoming Challenges. (40 citations)
- Covalent Modification of Biomolecules through Maleimide-Based Labeling Strategies (35 citations)
- Potent 3-Hydroxy-2-Pyridine Aldoxime Reactivators of Organophosphate-Inhibited Cholinesterases with Predicted Blood-Brain Barrier Penetration. (27 citations)
In his most recent research, the most cited papers focused on:
- Organic chemistry
- Enzyme
- Catalysis
Acetylcholinesterase, Stereochemistry, Oxime, Aché and Pharmacology are his primary areas of study.
His Acetylcholinesterase study is concerned with the field of Enzyme as a whole.
His work is dedicated to discovering how Enzyme, In vitro are connected with Pharmacophore and other disciplines.
His Stereochemistry research is multidisciplinary, incorporating perspectives in Bifunctional, Lectin and Isothiocyanate.
His Oxime study incorporates themes from Morpholine and Paraoxon.
His research investigates the connection between Aché and topics such as Drug that intersect with problems in Zeta potential.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
